Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2014

Open Access 01-12-2014 | Oral presentation

Translational research in the genomic era: OPPERA study

Author: Luda Diatchenko

Published in: Molecular Pain | Special Issue 1/2014

Login to get access

Excerpt

Temporomandibular Disorder (TMD) tends to coexist with other chronic pain conditions in affected individuals and is characterized by a report of pain greater than expected based on the results of a standard physical evaluation. The pathophysiology of this condition is largely unknown, the scientific field lacks biological markers for accurate diagnosis, and conventional therapeutics have limited effectiveness. Growing evidence suggests that chronic pain conditions are associated with both physical and psychological triggers, which initiate pain amplification and psychological distress; thus, susceptibility is dictated by complex interactions between genetic and environmental factors [1]. …
Literature
1.
Maixner W, Diatchenko L, Dubner R, Fillingim RB, Greenspan JD, Knott C, Ohrbach R, Weir B, Slade GD: Orofacial pain prospective evaluation and risk assessment study--the OPPERA study. J Pain 2011,12(11 Suppl):T4–11.e1–2.PubMedCentralPubMedCrossRef
2.
Smith SB, Maixner DW, Greenspan JD, Dubner R, Fillingim RB, Ohrbach R, Knott C, Slade GD, Bair E, Gibson DG, Zaykin DV, Weir BS, Maixner W, Diatchenko L: Potential genetic risk factors for chronic TMD: genetic associations from the OPPERA case control study. J Pain 2011,12(11 Suppl):T92–101.PubMedCentralPubMedCrossRef
3.
Smith SB, Mir E, Bair E, Slade GD, Dubner R, Fillingim RB, Greenspan JD, Ohrbach R, Knott C, Weir B, Maixner W, Diatchenko L: Genetic variants associated with development of TMD and its intermediate phenotypes: the genetic architecture of TMD in the OPPERA prospective cohort study. J Pain 2013,14(12 Suppl):T91–101.PubMedCrossRef
Metadata
Title
Translational research in the genomic era: OPPERA study
Author
Luda Diatchenko
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Pain / Issue Special Issue 1/2014
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-10-S1-O1

Other articles of this Special Issue 1/2014

Molecular Pain 1/2014 Go to the issue

Oral presentation

Roles of COMT, NPY and GCH1 in acute and chronic pain/stress response

Oral presentation

Preclinical and translational studies of fenobam, an mGlu5 NAM, for the treatment of pain

Poster presentation

Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex for treating facial neuropathic pain – preliminary results of a randomized, sham-controlled, cross-over study

Poster presentation

Confocal microscopy reveals nerve fiber similarities in fibromyalgia and patients with dry eyes with a normal ophthalmic exam

Poster presentation

Case-control analysis in resting and evoked inflammatory profiles

Oral presentation

Targeted genome and epigenome editing using engineered TALE and CRISPR/Cas9 technologies